Summary
- Current Price
- As of today, ABBV price is $265.97, up +2.72% on
- Current Price All-Time High
- ABBV price is currently -0.56% below its historical high of $267.47 set on
- Market Cap
- ABBV current market cap is $470B, up +27.21% over the past 365 days
- PE Ratio
- ABBV current PE ratio is 75.20
- Revenue
- ABBV current annual revenue is $61.16B, up +8.57% year-over-year
- Next Earnings
- The next earnings release for ABBV is on
Profile
| Metric | Value |
|---|---|
| Full Name | AbbVie Inc. |
| Ticker | NYSE: ABBV |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | General Drug Manufacturers |
| Country | United States |
| IPO | |
| Indexes | |
| Website | abbvie.com |
| Employees | 55,000 |
Key Metrics
| Metric | Value | Date |
|---|---|---|
| Price | $265.97 | |
| Price, 1D Change | +2.72% | |
| Market Cap | $470B | |
| TTM Dividend Yield | 2.57% | |
| PE Ratio | 75.20 | |
| Beta | -0.08 | |
| Revenue | $61.16B | |
| Revenue, 1Y Change | +8.57% | |
| EPS | $2.36 | |
| EPS, 1Y Change | -1.23% |
Chart
SUGGESTED SERIES
Events
| Metric | Value | Date |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | $1.73 | |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Value | Date |
|---|---|---|
| EPS | $2.36 | |
| EPS Estimate | $14.01 | N/A |
| EPS Est. Change | +493.36% | N/A |
| Revenue | $61.16B | |
| Revenue Estimate | $67.58B | N/A |
| Revenue Est. Change | +10.50% | N/A |
| Current Price | $265.97 | |
| Price Target | $280.00 | - |
| Price Tgt. Change | +5.28% | - |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $10.45 | $2.39 | -77.13% | |
| $9.94 | $2.36 | -76.24% | |
| $14.01 | N/A | +493.36% | |
| $16.26 | N/A | +588.64% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $56.04B | $56.33B | +0.52% | |
| $60.96B | $61.16B | +0.33% | |
| $67.58B | N/A | +10.50% | |
| $73.51B | N/A | +20.19% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Value | Date |
|---|---|---|
| Price, 1Y | +27.17% | |
| Price, 3Y | +77.15% | |
| Market Cap, 1Y | +27.21% | |
| Market Cap, 3Y | +77.38% | |
| Revenue, 1Y | +8.57% | |
| Revenue, 3Y | +5.35% | |
| EPS, 1Y | -1.23% | |
| EPS, 3Y | -64.37% |
🔒 Log In To Unlock Full Data
Technicals
| Metric | Value | Date |
|---|---|---|
| Current Price | $265.97 | |
| SMA 200 | $225.97 | |
| SMA 50 | $245.92 | |
| EMA 200 | $226.71 | |
| EMA 50 | $244.87 | |
| MACD | $2.49 | |
| Beta | -0.08 | |
| ATR | $6.30 | |
| 14-Day RSI | 67.39 | |
| 10-Day Volatility | 21.08% |
Dividends
| Metric | Value | Date |
|---|---|---|
| Last Paid | $1.73 | |
| Upcoming | N/A | N/A |
| Dividend Yield | 2.47% | |
| Total Dividend | $6.56 | |
| Dividends Paid | $11.66B | |
| Payout Ratio | 278.01% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Value | Date |
|---|---|---|
| Revenue | $61.16B | |
| EPS | $2.36 | |
| Gross Profit | $51.20B | |
| Gross Margin | 83.71% | |
| Operating Income | $21.21B | |
| Operating Margin | 34.69% | |
| Net Income | $4.19B | |
| Net Margin | 6.92% | |
| EBITDA | $29.05B |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Value | Date |
|---|---|---|
| Debt To Equity | -20.91 | |
| Current Ratio | 0.67 | |
| Quick Ratio | 0.56 | |
| - | ||
| Piotroski F-Score | 8 | |
| Altman Z-Score | 2.75 |
Valuations
Balance Sheet
| Metric | Value | Date |
|---|---|---|
| Book Value | -$3.27B | |
| Cash & Equivalents | $5.26B | |
| Total Assets | $133.96B | |
| Current Assets | $29.06B | |
| Total Liabilities | $137.19B | |
| Current Liabilities | $43.29B | |
| Total Debt | $68.38B | |
| Short Term Debt | $8.75B | |
| Accounts Payable | $3.59B |
Expenses
| Metric | Value | Date |
|---|---|---|
| Total Expenses | $56.93B | |
| Operating Expenses | $29.98B | |
| Cost Of Goods Sold | $9.97B | |
| SG&A | $0.00 | |
| D&A | $8.14B | |
| Interest Expense | $0.00 | |
| Income Tax | $2.36B |
Cash Flow
| Metric | Value | Date |
|---|---|---|
| CFO | $19.03B | |
| CFI | -$6.64B | |
| CFF | -$12.72B | |
| Capex | $1.21B | |
| Free Cash Flow | $17.82B |
Recent analyst updates
| Metric | Value | Date |
|---|---|---|
| Wolfe Research | → | |
| BNP Paribas | → | |
| Evercore ISI Group | → | |
| Guggenheim | → | |
| Cantor Fitzgerald | → | |
| Canaccord Genuity | → | |
| Barclays | → | |
| Canaccord Genuity | → | |
| Citigroup | → | |
| UBS | → |
Analyst sentiment
Institutional ownership
Screeners with ABBV
FAQ
- What is the ticker symbol for AbbVie Inc.?
- The ticker symbol for AbbVie Inc. is NYSE:ABBV
- Does AbbVie Inc. pay dividends?
- Yes, AbbVie Inc. pays dividends. The last payment was $1.73, with an ex-dividend date on July 15, 2026
- What sector is AbbVie Inc. in?
- AbbVie Inc. is in the Healthcare sector
- What industry is AbbVie Inc. in?
- AbbVie Inc. is in the General Drug Manufacturers industry
- What country is AbbVie Inc. based in?
- AbbVie Inc. is headquartered in United States
- When did AbbVie Inc. go public?
- AbbVie Inc. initial public offering (IPO) was on January 2, 2013
- Is AbbVie Inc. in the S&P 500?
- Yes, AbbVie Inc. is included in the S&P 500 index
- Is AbbVie Inc. in the NASDAQ 100?
- No, AbbVie Inc. is not included in the NASDAQ 100 index
- Is AbbVie Inc. in the Dow Jones?
- No, AbbVie Inc. is not included in the Dow Jones index
- When was AbbVie Inc. last earnings report?
- AbbVie Inc.'s most recent earnings report was on July 31, 2026
- When does AbbVie Inc. report earnings?
- The next expected earnings date for AbbVie Inc. is October 29, 2026
Data Sources & References
- ABBV Official Website www.abbvie.com
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1551152/000155115226000008/0001551152-26-000008-index.htm
- List of S&P 500 Companies www.spglobal.com/spdji/en/indices/equity/sp-500/#overview
- ABBV Profile on Yahoo Finance finance.yahoo.com/quote/ABBV
- ABBV Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/abbv